Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.

Keywords: Allogeneic stem cell transplantation; COVID-19; Graft-versus-host disease; Immunocompromised; JAK inhibitor.

Figure 1

Axial (A) and Coronal (B) Images From the Patient’s Chest Computed Tomography Demonstrate Diffuse Centrilobular Ground Glass Nodules (Circles) as Well as Subtle, Patchy Ground Glass Opacity in the Right Upper Lobe (Arrows). These Findings are Nonspecific but are Typically Seen in the Setting of Infectious (Such as Viral or Opportunistic Infections) or Inflammatory Disorders (Such as Drug Toxicity or Hypersensitivity Pneumonitis) and Have an Indeterminate Appearance for COVID-19 Pneumonia

Figure 2

Time Course of CRP and Temperature in Fahrenheit Abbreviation: CRP = C-reactive protein.